The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Official Title: Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma
Study ID: NCT01513187
Brief Summary: Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the first stage it will determine the optimal dose of the combination of pazopanib and interferon alfa-A2 in the treatment of patients with advanced renal carcinoma and a second stage that will determine the efficacy of this combination measured in terms of response rate.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Instituto Catalán de Oncología, Hospitalet del Llobregat, Hospitalet de Llobregat, Barcelona, Spain
Centro Integral Oncológico Clara Campal, Sanchinarro, Sanchinarro - Madrid, Spain
Hospital del Mar, Barcelona, , Spain
Hospital Clínic, Barcelona, , Spain
Hospital Clínico San Carlos, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Central de Asturias, Oviedo, , Spain
Hospital Son Espases, Palma, , Spain
Clinica Univ. Navarra, Pamplona, , Spain
Hospital Virgen de la Macarena, Sevilla, , Spain
Hospital Virgen del Rocio, Sevilla, , Spain
Hospital Virgen de la Salud, Toledo, , Spain
IVO, Valencia, , Spain
Name: Xavier García del Muro, MD
Affiliation: Instituto Catalán de Oncología, Hospitalet del Llobregat
Role: PRINCIPAL_INVESTIGATOR